Supplementary Materials

Supplementary Material for:

Broadly neutralizing human monoclonal JC polyomavirus VP1–specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy

Ivan Jelcic, Benoit Combaluzier, Ilijas Jelcic, Wolfgang Faigle, Luzia Senn, Brenda J. Reinhart, Luisa Ströh, Roger M. Nitsch, Thilo Stehle, Mireia Sospedra, Jan Grimm,* Roland Martin*

*Corresponding author. E-mail: roland.martin{at}usz.ch (R.M.); jan.grimm{at}neurimmune.com (J.G.)

Published 23 September 2015, Sci. Transl. Med. 7, 306ra150 (2015)
DOI: 10.1126/scitranslmed.aac8691

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Mutations in JCPyV viral capsid protein VP1.
  • Fig. S2. Recognition of JCPyV VP1/VLP variants by human monoclonal antibodies.
  • Fig. S3. Cross-competition assay of VP1-specific monoclonal antibodies.
  • Fig. S4. Differences between JCPyV and BKPyV VP1.
  • Fig. S5. Recognition of denatured JCPyV VP1 and BKPyV VP1 (Western blot).

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Source data in tabular form (separate Excel file)

[Download Source Data]